In March 2022, FDA approved Lutetium-177 PSMA-617 (as Lutetium-177-PSMA or 177Lu-vipivotide tetraxetan, Pluvicto) as a radioligand target with PSMA, to become the treatment for metastatic, castration-resistant, and refractory prostate cancer in recent years. Here, FOLH1 is linked to prostate cancer.